These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 7887367)
21. Major issues in marketing regulation. Pines WL Food Drug Law J; 1997; 52(3):297-302. PubMed ID: 10343028 [No Abstract] [Full Text] [Related]
22. Pitfalls of drug manufacturing--an evaluation of 18 months of FDA recalls. Frediani HA Bull Parenter Drug Assoc; 1972; 26(4):172-81. PubMed ID: 5067998 [No Abstract] [Full Text] [Related]
23. FDA drug information that never reaches clinicians. Casoy J N Engl J Med; 2010 Feb; 362(6):561; author reply 563. PubMed ID: 20175299 [No Abstract] [Full Text] [Related]
24. The federal preemption debate in pharmaceutical labeling product liability actions. Gross JM; Curry JA Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866 [No Abstract] [Full Text] [Related]
26. Members of new FDA board tied to industry. Finkelstein JB J Natl Cancer Inst; 2008 Mar; 100(5):296-7. PubMed ID: 18314467 [No Abstract] [Full Text] [Related]
27. FDA's regulation of prescription drug labeling: a role for implied preemption. Kendrick LC Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031 [No Abstract] [Full Text] [Related]
28. FDA to steer nanotech. Fox JL Nat Biotechnol; 2008 Oct; 26(10):1060. PubMed ID: 18846060 [No Abstract] [Full Text] [Related]
29. FDA tightens rules on advertising. Josefson D BMJ; 1997 Aug; 315(7106):447. PubMed ID: 9284658 [No Abstract] [Full Text] [Related]
30. Maker of growth hormone feels long arm of law. Nordenberg T FDA Consum; 1999; 33(5):33. PubMed ID: 10522170 [No Abstract] [Full Text] [Related]
31. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption. Poser S Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225 [No Abstract] [Full Text] [Related]
32. FDA user fee plan gets some support from drug makers. Weissenstein E Mod Healthc; 1992 Aug; 22(33):20. PubMed ID: 10119804 [No Abstract] [Full Text] [Related]
33. FDA notifications. FDA approves label change for nevirapine. AIDS Alert; 2008 Aug; 23(8):91-2. PubMed ID: 18724490 [No Abstract] [Full Text] [Related]
34. Should the FDA regulate pharmacoeconomic studies? Robinson M HMO; 1996; 37(1):71-5. PubMed ID: 10159353 [No Abstract] [Full Text] [Related]
35. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
36. Deterring the importation of counterfeit pharmaceutical products. Stearn DW Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351 [No Abstract] [Full Text] [Related]
37. FDA proposes changes in sunscreen regulations. DeSimone EM Am Pharm; 1994 Jun; NS34(6):26-31. PubMed ID: 8059682 [No Abstract] [Full Text] [Related]
38. The professional society circus. Kassirer JP J Public Health Policy; 2005 Dec; 26(4):400-3. PubMed ID: 16392739 [No Abstract] [Full Text] [Related]
39. A defense of the learned intermediary doctrine. Goetz RB; Growdon KR Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470 [No Abstract] [Full Text] [Related]
40. FDA considers tightening regulations for direct-to-consumer advertising. Vastag B J Natl Cancer Inst; 2005 Dec; 97(24):1806-7. PubMed ID: 16368941 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]